Keywords: regranex, launched, usa, johnson, genetically-engineered, platelet-derived, growthfactor

J&J's Regranex Launched In USA

Article | 21 April 1998

Johnson & Johnson's genetically-engineered platelet-derived growthfactor Regranex (becaplermin 0.01%) has been launched in the USA, its first market, for the treatment of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Johnson & Johnson

Go to company listing

Related Drugs

Becaplermin

Regranex

Go to drug listing